Company will showcase technologies for brachytherapy, intensity-modulated radiotherapy (IMRT), RapidArc(TM) radiotherapy, and stereotactic body radiotherapy (SBRT)
PALO ALTO, Calif., April 24 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) will showcase the company's full spectrum of prostate cancer treatment technologies at the upcoming American Urological Association (AUA) Meeting at McCormick Place in Chicago from April 25-30.
"Varian offers state-of-the-art technology for all five of the commonly-used radiotherapy approaches to treating prostate cancer," said Calvin Huntzinger, MS, senior director, Varian Surgical Sciences. "At the AUA meeting, we'll be exhibiting our latest solutions for high-dose-rate brachytherapy, planning for low-dose brachytherapy with permanent seed implants, 3-D conformal radiotherapy, intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy (SBRT)." Each is a different approach to targeting prostate tumors with radiation.
"By offering technology for all radiotherapy treatment techniques, Varian is giving doctors and patients the option of deciding the best approach for treating each case," Huntzinger said. "That is where the decision belongs."
Varian recently produced a "Clinical Perspectives" paper entitled Early-stage prostate cancer treatment alternatives, highlighting research that contrasts these and other approaches to prostate cancer treatment.
"The paper summarizes the results of clinical studies on the treatment of prostate cancer," Huntzinger said. "It shows that surgery doesn't always eliminate the cancer, and it has other significant acute and chronic side effects. Non-invasive external beam radioth
'/>"/>
| SOURCE Varian Medical Systems, Inc. Copyright©2009 PR Newswire. All rights reserved |